In Second Deal in 2 Days, Pyrosequencing Pens Diagnostics Agreement with GCI | GenomeWeb

NEW YORK, Nov. 6 – Pyrosequencing and Genomics Collaborative said Tuesday that they had agreed to jointly collaborate to generate genomic information that could be used to develop diagnostics and therapeutic products for cardiovascular disease.

The deal is Pyrosequencing’s second such deal in the diagnostics market in as many days. On Monday, the Uppsala, Sweden-based company announced that it would work with the Cleveland Clinic to co-develop rapid identification and diagnostic tests for mycobacteria.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.